An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies
The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
Currently participating or participated recently in a BeiGene parent study
Intent to continue or start zanubrutinib treatment after any of the following:
Patient who is currently on zanubrutinib treatment:
Does not meet any protocol-specified criteria for zanubrutinib hold or permanent discontinuation, and, in the opinion of the investigator, will continue to benefit from zanubrutinib treatment
Zanubrutinib-naive patient:
Must meet the following criteria ≤ 15 days before first dose of study drug:
Female participants of childbearing potential and nonsterile males must be willing to use a highly effective method of birth control.
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Bedford PK, South Australia 5042, Australia
Wuhan, Hubei 430022, China
Wuhan, Hubei 430030, China
Shanghai, Shanghai Municipality 200092, China
Hangzhou, Zhejiang 310003, China
PierreBenite, 69495, France
Hamilton Waikato, 3204, New Zealand
Gdask, 80-219, Poland
Skorzewo Poznan, 60-185, Poland
Greater Manchester, M20 4BX, United Kingdom